Patients will be randomised to get either HA-Irinotecan or irinotecan. The principal endpoint will be tumor stem cell burden during and at the conclusion of the scholarly study. On the safety aspect, the trial shall gauge the incidence of quality 3 and 4 toxicity. Secondary endpoints include Progression-Free Survival . Alchemia will contribute the study drug, HA-Irinotecan, and will be responsible for the evaluation of circulating tumour cells and malignancy stem cells. That is a proof concept trial for a very promising therapy, stated Principal investigator Dr. Vinod Ganju. There are few treatment options for patients with small cell lung cancer and, based on the previous experience with HA-Irinotecan in colorectal cancer, we hope to see improved individual outcomes.Bumpy scars are often treated with injections of an intralesional steroid. Lasers may be used in treating scars, but they can be expensive.
Karl Swedberg, M.D., Ph.D., James B. Young, M.D., Inder S. Anand, M.D., Sunfa Cheng, M.D., Akshay S. Desai, M.D., Rafael Diaz, M.D., Aldo P. Maggioni, M.D., John J.V. McMurray, M.D., Christopher O’Connor, M.D., Marc A. Pfeffer, M.D., Ph.D., Scott D. Solomon, M.D., Yan Sunlight, M.S., Michal Tendera, M.D., and Dirk J.